Secretin ELISA Kit

Sluggish cognitive tempo (SCT) is characterized by behavioral symptoms reflecting slowness and lethargy (e.g., sluggishness, appearing sleepy) and inconsistent alertness/mental confusion (e.g., daydreaming, fogginess). SCT is substantially correlated with the inattentive symptoms of attention-deficit/hyperactivity disorder (ADHD) and may be part of that domain, but in cross-sectional data, SCT is also strongly associated with both inattention and depression. To date, no study has examined the prospective associations of SCT symptoms in childhood/adolescence with symptoms of ADHD and internalizing problems in adulthood. Using a sample of 449 twin children and adolescent pairs, prospective multiple regression analyses examined whether self- and parent-reported SCT, depression, and parent-reported symptoms of ADHD predicted symptoms in adulthood 12 years later. SCT and depression at time one were strongly correlated (self-reported SCT and depressionr = 0.84; parent-reported SCT and depressionr = 0.78). When adult outcomes were separately regressed on each youth symptom dimension, self-reported SCT (beta = 0.26,p < 0.0001) and depression (beta = 0.13,p < 0.0001) each predicted adult symptoms of depression and self-reported SCT predicted inattention (beta = 0.12,p = 0.0026). Parent-reported depression, but not parent-reported SCT, predicted self-reported adult depression symptoms (beta = 0.17,p = 0.0003). In contrast, when each adult outcome was regressed simultaneously on youth self-reported SCT and depression, neither predicted adulthood inattention or depression. These findings indicate that SCT in childhood and adolescence is strongly associated concurrently and predictively with both inattention and depression. Theoretical and clinical applications of the construct of SCT must take its robust association with both inattention and depression into account.

Background Autologous stem cell transplantation (auto-SCT) is a treatment approach in non-Hodgkin lymphoma (NHL) patients. The options for mobilization of CD34(+) cells to support high-dose therapy are granulocyte-colony stimulating factors (G-CSFs) alone or after chemotherapy. Limited data exist on the efficacy of lipegfilgrastim (LIPEG) in the mobilization field. Patients and Methods The present prospective nonrandomized study compared LIPEG 6 mg (n = 40) with pegfilgrastim (PEG) 6 mg (n = 37) in the mobilization of blood CD34(+) cells after chemotherapy in NHL patients with comparable mobilizing chemotherapy and disease status before auto-SCT. Results Significantly higher blood CD34(+) cell (B-CD34(+)) counts were observed in the LIPEG group at the start of the first apheresis (44 vs 23 x 10(6)/L, P = .009), in line with a higher collection yield of the first apheresis (3.3 vs 2.1 x 10(6)/kg, P = .086) and total yield of CD34(+) cells (4.7 vs 2.9 x 10(6)/kg, P = .004). LIPEG proved to be a more effective G-CSF, resulting in a higher B-CD34(+) cell peak (60 vs 32 x 10(6)/L, P = .030) and higher proportion of excellent mobilizers (33% vs 8%, P = .008). The superiority of LIPEG was confirmed in the multivarite analysis concerning the CD34(+) cell yield of the first apheresis day (P = .010) and the total yield (P = .001). Conclusion The mobilization of blood grafts with LIPEG added to chemotherapy was associated with higher CD34(+) cell apheresis yields than with PEG. A randomized study is warranted to verify these findings.